Henry Schein (HSIC) Competitors

Repligen (NASDAQ:RGEN) and Henry Schein (NASDAQ:HSIC) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.

Do analysts prefer RGEN or HSIC?

Repligen currently has a consensus target price of $197.75, suggesting a potential upside of 26.16%. Henry Schein has a consensus target price of $81.73, suggesting a potential upside of 14.87%. Given Henry Schein's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Henry Schein.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Henry Schein	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Which has higher valuation & earnings, RGEN or HSIC?

Henry Schein has higher revenue and earnings than Repligen. Henry Schein is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$638.76M	13.71	$41.58M	$0.25	627.03
Henry Schein	$12.45B	0.73	$416M	$2.96	24.04

Is RGEN or HSIC more profitable?

Henry Schein has a net margin of 3.12% compared to Henry Schein's net margin of 2.44%. Repligen's return on equity of 13.51% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	2.44%	3.95%	2.90%
Henry Schein	3.12%	13.51%	5.79%

Which has more risk & volatility, RGEN or HSIC?

Repligen has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Henry Schein has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Does the media favor RGEN or HSIC?

In the previous week, Repligen had 13 more articles in the media than Henry Schein. MarketBeat recorded 21 mentions for Repligen and 8 mentions for Henry Schein. Repligen's average media sentiment score of 0.87 beat Henry Schein's score of 0.78 indicating that Henry Schein is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Henry Schein	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of RGEN or HSIC?

97.6% of Repligen shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 1.2% of Repligen shares are held by company insiders. Comparatively, 1.1% of Henry Schein shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer RGEN or HSIC?

Repligen received 34 more outperform votes than Henry Schein when rated by MarketBeat users. Likewise, 68.08% of users gave Repligen an outperform vote while only 51.54% of users gave Henry Schein an outperform vote.

Company	Underperform	Outperform
Repligen	Outperform Votes 401 68.08%	Underperform Votes 188 31.92%
Henry Schein	Outperform Votes 367 51.54%	Underperform Votes 345 48.46%

Summary

Repligen beats Henry Schein on 11 of the 18 factors compared between the two stocks.